It is not
for sure (!), BUT it is very close to be true that in the nearest future we will
get another candidate: Bavituximab (sure - the monoclonal antibody!)
Peregrine (the company owned the medicine – my comment) has been working on Bavi (the short name of the
drug – my comment) for nine
years and still has not even reached Phase III. It has been working on Cotara (another
drug of the company – my comment) for an even longer period of time, and Cotara has now been put on the
back burner after Peregrine stoked shareholders' hopes for years with press
releases about Cotara's Phase II trials. Normally drugs that are actually
game-changing treatments reveal their amazing capabilities in a shorter period
of time, particularly for diseases that have median survival periods of only a
few months. If either Cotara or Bavi were revolutionary treatments, it seems
unlikely that they would have needed nearly a decade to prove themselves. And
if Bavi were really an amazing treatment for a variety of cancers, we would
think that another pharma company would have recognized that by now and already
partnered with Peregrine.
What “targeted”
candidate will be next?
No comments:
Post a Comment